Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Endothelin Receptor Antagonists (ERA)
      • 1.3.3 Prostacyclin And Prostacyclin Analogs
      • 1.3.4 Phosphodiesterase 5 (PDE-5)
      • 1.3.5 Soluble Guanylate Cyclase (SGC) Stimulators
    • 1.4 Market Segment by Application
      • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application (2019-2025)
      • 1.4.2 Secondary Pulmonary Hypertension (SPH)
      • 1.4.3 Primary Pulmonary Hypertension (PPH)
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size
      • 2.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2014-2025
      • 2.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales 2014-2025
    • 2.2 Pulmonary Arterial Hypertension (PAH) Medicine Growth Rate by Regions
      • 2.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Regions 2014-2019
      • 2.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Pulmonary Arterial Hypertension (PAH) Medicine Sales by Manufacturers
      • 3.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Sales by Manufacturers 2014-2019
      • 3.1.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Ratio (CR5 and HHI)
    • 3.3 Pulmonary Arterial Hypertension (PAH) Medicine Price by Manufacturers
    • 3.4 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Medicine Market
    • 3.6 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Endothelin Receptor Antagonists (ERA) Sales and Revenue (2014-2019)
      • 4.1.2 Prostacyclin And Prostacyclin Analogs Sales and Revenue (2014-2019)
      • 4.1.3 Phosphodiesterase 5 (PDE-5) Sales and Revenue (2014-2019)
      • 4.1.4 Soluble Guanylate Cyclase (SGC) Stimulators Sales and Revenue (2014-2019)
    • 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type
    • 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type
    • 4.4 Pulmonary Arterial Hypertension (PAH) Medicine Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

    6 United States

    • 6.1 United States Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Company
    • 6.2 United States Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Type
    • 6.3 United States Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Application

    7 European Union

    • 7.1 European Union Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Company
    • 7.2 European Union Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Type
    • 7.3 European Union Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Application

    8 China

    • 8.1 China Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Company
    • 8.2 China Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Type
    • 8.3 China Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Company
    • 9.2 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Type
    • 9.3 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Application
    • 9.4 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Countries
      • 9.4.1 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Sales by Countries
      • 9.4.2 Rest of World Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Actelion Pharmaceuticals
      • 10.1.1 Actelion Pharmaceuticals Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.1.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.1.5 Actelion Pharmaceuticals Recent Development
    • 10.2 Gilead Sciences
      • 10.2.1 Gilead Sciences Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.2.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.2.5 Gilead Sciences Recent Development
    • 10.3 United Therapeutics Corporation
      • 10.3.1 United Therapeutics Corporation Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.3.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.3.5 United Therapeutics Corporation Recent Development
    • 10.4 GlaxoSmithKline
      • 10.4.1 GlaxoSmithKline Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.4.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.4.5 GlaxoSmithKline Recent Development
    • 10.5 Pfizer
      • 10.5.1 Pfizer Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.5.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.5.5 Pfizer Recent Development
    • 10.6 Bayer HealthCare
      • 10.6.1 Bayer HealthCare Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.6.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.6.5 Bayer HealthCare Recent Development
    • 10.7 Arena Pharmaceuticals
      • 10.7.1 Arena Pharmaceuticals Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension (PAH) Medicine
      • 10.7.4 Pulmonary Arterial Hypertension (PAH) Medicine Product Introduction
      • 10.7.5 Arena Pharmaceuticals Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels
      • 11.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
    • 11.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers

    12 Market Forecast

    • 12.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales and Revenue Forecast 2019-2025
    • 12.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Type
    • 12.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Application
    • 12.4 Pulmonary Arterial Hypertension (PAH) Medicine Forecast by Regions
      • 12.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Pulmonary Arterial Hypertension (PAH) Medicine is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Pulmonary Arterial Hypertension (PAH) Medicine.

      This report studies the global market size of Pulmonary Arterial Hypertension (PAH) Medicine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Pulmonary Arterial Hypertension (PAH) Medicine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Actelion Pharmaceuticals
      Gilead Sciences
      United Therapeutics Corporation
      GlaxoSmithKline
      Pfizer
      Bayer HealthCare
      Arena Pharmaceuticals
      ...

      Market Segment by Product Type
      Endothelin Receptor Antagonists (ERA)
      Prostacyclin And Prostacyclin Analogs
      Phosphodiesterase 5 (PDE-5)
      Soluble Guanylate Cyclase (SGC) Stimulators

      Market Segment by Application
      Secondary Pulmonary Hypertension (SPH)
      Primary Pulmonary Hypertension (PPH)

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Pulmonary Arterial Hypertension (PAH) Medicine status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Pulmonary Arterial Hypertension (PAH) Medicine manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension (PAH) Medicine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now